Summary | |
---|---|
Symbol | UBE3A |
Name | ubiquitin protein ligase E3A |
Aliases | E6-AP; FLJ26981; Angelman syndrome; EPVE6AP; HPVE6A; human papilloma virus E6-associated protein; CTCL tumor ...... |
Chromosomal Location | 15q11.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cytoplasm Nucleus |
Domain |
PF16558 Amino-terminal Zinc-binding domain of ubiquitin ligase E3A PF00632 HECT-domain (ubiquitin-transferase) |
Function |
E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and transfers it to its substrates (PubMed:10373495, PubMed:16772533, PubMed:19204938, PubMed:19233847, PubMed:19325566, PubMed:19591933, PubMed:22645313, PubMed:24273172, PubMed:24728990). Several substrates have been identified including the ARNTL/BMAL1, ARC, RAD23A and RAD23B, MCM7 (which is involved in DNA replication), annexin A1, the PML tumor suppressor, and the cell cycle regulator CDKN1B (PubMed:10373495, PubMed:19204938, PubMed:19325566, PubMed:19591933, PubMed:22645313, PubMed:24728990). Additionally, may function as a cellular quality control ubiquitin ligase by helping the degradation of the cytoplasmic misfolded proteins (PubMed:19233847). Finally, UBE3A also promotes its own degradation in vivo. Plays an important role in the regulation of the circadian clock: involved in the ubiquitination of the core clock component ARNTL/BMAL1, leading to its proteasomal degradation (PubMed:24728990). Acts as transcriptional coactivator of progesterone receptor PGR upon progesterone hormone activation (PubMed:16772533). Acts as a regulator of synaptic development by mediating ubiquitination and degradation of ARC (By similarity). Synergizes with WBP2 in enhancing PGR activity (PubMed:16772533). ; FUNCTION: (Microbial infection) Catalyzes the high-risk human papilloma virus E6-mediated ubiquitination of p53/TP53, contributing to the neoplastic progression of cells infected by these viruses. |
Biological Process |
GO:0000209 protein polyubiquitination GO:0001541 ovarian follicle development GO:0001655 urogenital system development GO:0007338 single fertilization GO:0007548 sex differentiation GO:0007623 circadian rhythm GO:0008406 gonad development GO:0008585 female gonad development GO:0009566 fertilization GO:0009755 hormone-mediated signaling pathway GO:0009894 regulation of catabolic process GO:0014065 phosphatidylinositol 3-kinase signaling GO:0014066 regulation of phosphatidylinositol 3-kinase signaling GO:0014068 positive regulation of phosphatidylinositol 3-kinase signaling GO:0022602 ovulation cycle process GO:0030518 intracellular steroid hormone receptor signaling pathway GO:0030521 androgen receptor signaling pathway GO:0030522 intracellular receptor signaling pathway GO:0030850 prostate gland development GO:0031329 regulation of cellular catabolic process GO:0031396 regulation of protein ubiquitination GO:0031398 positive regulation of protein ubiquitination GO:0035037 sperm entry GO:0035265 organ growth GO:0042176 regulation of protein catabolic process GO:0042698 ovulation cycle GO:0042752 regulation of circadian rhythm GO:0042787 protein ubiquitination involved in ubiquitin-dependent protein catabolic process GO:0043401 steroid hormone mediated signaling pathway GO:0045137 development of primary sexual characteristics GO:0046545 development of primary female sexual characteristics GO:0046660 female sex differentiation GO:0048015 phosphatidylinositol-mediated signaling GO:0048017 inositol lipid-mediated signaling GO:0048511 rhythmic process GO:0048545 response to steroid hormone GO:0048608 reproductive structure development GO:0048732 gland development GO:0051865 protein autoubiquitination GO:0060736 prostate gland growth GO:0061458 reproductive system development GO:0070936 protein K48-linked ubiquitination GO:0071383 cellular response to steroid hormone stimulus GO:0071396 cellular response to lipid GO:0071407 cellular response to organic cyclic compound GO:1903050 regulation of proteolysis involved in cellular protein catabolic process GO:1903320 regulation of protein modification by small protein conjugation or removal GO:1903322 positive regulation of protein modification by small protein conjugation or removal GO:1903362 regulation of cellular protein catabolic process GO:2000058 regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process |
Molecular Function |
GO:0003713 transcription coactivator activity GO:0004842 ubiquitin-protein transferase activity GO:0019787 ubiquitin-like protein transferase activity GO:0061630 ubiquitin protein ligase activity GO:0061659 ubiquitin-like protein ligase activity |
Cellular Component |
GO:0000502 proteasome complex GO:1905368 peptidase complex GO:1905369 endopeptidase complex |
KEGG |
hsa04120 Ubiquitin mediated proteolysis |
Reactome |
R-HSA-1280218: Adaptive Immune System R-HSA-983168: Antigen processing R-HSA-983169: Class I MHC mediated antigen processing & presentation R-HSA-168256: Immune System |
Summary | |
---|---|
Symbol | UBE3A |
Name | ubiquitin protein ligase E3A |
Aliases | E6-AP; FLJ26981; Angelman syndrome; EPVE6AP; HPVE6A; human papilloma virus E6-associated protein; CTCL tumor ...... |
Chromosomal Location | 15q11.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between UBE3A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between UBE3A and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | UBE3A |
Name | ubiquitin protein ligase E3A |
Aliases | E6-AP; FLJ26981; Angelman syndrome; EPVE6AP; HPVE6A; human papilloma virus E6-associated protein; CTCL tumor ...... |
Chromosomal Location | 15q11.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of UBE3A in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | UBE3A |
Name | ubiquitin protein ligase E3A |
Aliases | E6-AP; FLJ26981; Angelman syndrome; EPVE6AP; HPVE6A; human papilloma virus E6-associated protein; CTCL tumor ...... |
Chromosomal Location | 15q11.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of UBE3A in various data sets.
|
Points in the above scatter plot represent the mutation difference of UBE3A in various data sets.
|
Summary | |
---|---|
Symbol | UBE3A |
Name | ubiquitin protein ligase E3A |
Aliases | E6-AP; FLJ26981; Angelman syndrome; EPVE6AP; HPVE6A; human papilloma virus E6-associated protein; CTCL tumor ...... |
Chromosomal Location | 15q11.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of UBE3A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | UBE3A |
Name | ubiquitin protein ligase E3A |
Aliases | E6-AP; FLJ26981; Angelman syndrome; EPVE6AP; HPVE6A; human papilloma virus E6-associated protein; CTCL tumor ...... |
Chromosomal Location | 15q11.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of UBE3A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by UBE3A. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | UBE3A |
Name | ubiquitin protein ligase E3A |
Aliases | E6-AP; FLJ26981; Angelman syndrome; EPVE6AP; HPVE6A; human papilloma virus E6-associated protein; CTCL tumor ...... |
Chromosomal Location | 15q11.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of UBE3A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | UBE3A |
Name | ubiquitin protein ligase E3A |
Aliases | E6-AP; FLJ26981; Angelman syndrome; EPVE6AP; HPVE6A; human papilloma virus E6-associated protein; CTCL tumor ...... |
Chromosomal Location | 15q11.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of UBE3A expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | UBE3A |
Name | ubiquitin protein ligase E3A |
Aliases | E6-AP; FLJ26981; Angelman syndrome; EPVE6AP; HPVE6A; human papilloma virus E6-associated protein; CTCL tumor ...... |
Chromosomal Location | 15q11.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between UBE3A and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | UBE3A |
Name | ubiquitin protein ligase E3A |
Aliases | E6-AP; FLJ26981; Angelman syndrome; EPVE6AP; HPVE6A; human papilloma virus E6-associated protein; CTCL tumor ...... |
Chromosomal Location | 15q11.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting UBE3A collected from DrugBank database. |
There is no record. |